# ZBTB32

## Overview
ZBTB32 is a gene that encodes the zinc finger and BTB domain containing 32 protein, a transcription factor involved in the regulation of gene expression, particularly within the immune system. The protein is characterized by its C-terminal C2H2/Krüppel-type zinc finger domains, which facilitate specific DNA binding, and an N-terminal BTB domain, which is crucial for protein-protein interactions and chromatin remodeling (Cheng2021ZBTB; Zhu2018Regulation). ZBTB32 plays a significant role in modulating immune responses by acting as a transcriptional repressor in B and T lymphocytes, influencing processes such as B cell differentiation and T cell activation (Cheng2021ZBTB; Yoon2012ZBTB32). Additionally, ZBTB32 interacts with various proteins, including the glucocorticoid receptor, to regulate cellular functions beyond the immune system, such as cholesterol metabolism (Van2021ZBTB32). The gene's expression is implicated in several diseases, including cancer and chronic lymphocytic leukemia, highlighting its potential as a biomarker and therapeutic target (Wang2021Fanconi; Upchurch2016Aberrant).

## Structure
ZBTB32 is a transcription factor characterized by the presence of C-terminal C2H2/Krüppel-type zinc finger (ZF) domains and an N-terminal BTB (broad-complex, tram-track, and bric-a-brac) domain. The BTB domain is crucial for protein-protein interactions, facilitating chromatin remodeling and gene silencing or activation by interacting with corepressors and histone/protein modification enzymes (Cheng2021ZBTB; Zhu2018Regulation). The zinc finger domains are responsible for binding to specific DNA sequences, thereby determining the transcriptional specificity of ZBTB32 (Cheng2021ZBTB; Zhu2018Regulation).

The linker region between the BTB and ZF domains is often subject to post-translational modifications, which can affect the stability and flexibility of the ZBTB32-DNA complex (Zhu2018Regulation). These modifications may include phosphorylation and ubiquitination, which influence the protein's function and stability.

While specific details about the molecular structure of ZBTB32, such as its secondary, tertiary, or quaternary structures, are not provided in the available context, the general structural features of ZBTB proteins, including ZBTB32, are well characterized by their BTB and ZF domains (Cheng2021ZBTB; Zhu2018Regulation).

## Function
ZBTB32, also known as zinc finger and BTB domain containing 32, is a transcriptional repressor that plays a significant role in the immune system by regulating gene expression in B and T lymphocytes. In B cells, ZBTB32 acts as a transcriptional repressor of CIITA, a key regulator of MHC class II genes, thereby influencing the differentiation of B cells into plasma cells (Yoon2012ZBTB32). This repression is crucial for modulating immune responses, as it helps control the duration and rapidity of memory B cell recall responses, limiting the lifespan of plasma cells during the activation phase (Zhu2018Regulation; Jash2016ZBTB32).

In T cells, ZBTB32 is involved in T-cell activation and proliferation. It is upregulated in T helper cells upon TCR stimulation and acts as a brake on T-cell activation by attenuating TCR signaling and inhibiting NF-kB binding to the Il2 promoter (Cheng2021ZBTB). In CD8+ T cells, ZBTB32 represses IL-4 expression by recruiting HDAC1 and HDAC2, maintaining a repressive chromatin state, and collaborates with PRDM1 to repress CD27 and Eomes, molecules that promote CD8+ Tm cell survival (Shin2017Transient; Cheng2021ZBTB). This regulation is essential for balancing effector and memory T cell populations during viral infections, preventing excessive immune activation and potential immunopathology (Shin2017Transient).

## Clinical Significance
Alterations in the expression of the ZBTB32 gene have been implicated in various diseases, particularly in the context of cancer and immune regulation. In cervical cancer (CC), ZBTB32 is downregulated, contrasting with other Fanconi anemia pathway-related genes that are upregulated. This downregulation is associated with a protective role against adverse outcomes in CC patients, potentially through immune-related regulatory processes rather than the Fanconi anemia pathway. ZBTB32's expression varies significantly among different stages of CC, suggesting its potential as a biomarker for early clinical screening. Overexpression of ZBTB32 in CC cells has been shown to decrease cell proliferation, migration, and invasion, indicating a tumor suppressor role (Wang2021Fanconi).

In chronic lymphocytic leukemia (CLL), ZBTB32 is upregulated, which may contribute to disease development. This upregulation is linked to aberrant promoter hypomethylation, suggesting a potential role in CLL pathogenesis (Upchurch2016Aberrant).

ZBTB32 also plays a role in regulating immune responses, particularly in memory B cells. It restrains the magnitude and duration of recall responses, which is crucial for maintaining immune balance. Dysregulation of ZBTB32 could potentially impact immune responses, although no direct link to autoimmune diseases has been established (Jash2019ZBTB32; Jash2016ZBTB32).

## Interactions
ZBTB32, also known as FAZF, is a transcription factor that interacts with various proteins and nucleic acids to regulate cellular functions. It binds to GATA3, repressing its ability to transactivate Th2 cytokine genes, and collaborates with PRDM1, HDAC1, and HDAC2 to repress the expression of CD27 and Eomes, which are involved in the persistence and survival of CD8+ Tm cells. ZBTB32 also recruits HDAC1 and HDAC2 to maintain a repressive chromatin state at the Il-4 locus in CD8+ Tc2 cells, suggesting its role as a transcription factor modulating T-cell activation and memory response (Cheng2021ZBTB).

ZBTB32 interacts with the glucocorticoid receptor (GR) and functions as a co-activator to induce the expression of the Scarb1 gene, crucial for cholesterol import during starvation. This interaction is enhanced by dexamethasone, a GR agonist, and is dependent on GR-ligand binding and conformational changes (Van2021ZBTB32). In A549 human lung epithelial cells, ZBTB32 increases GR transcriptional activity in response to dexamethasone, although it is not essential for GR-DNA binding to the Scarb1 promoter (Van2021ZBTB32). Co-immunoprecipitation experiments have confirmed the physical interaction between ZBTB32 and GR in both cell lysates and adrenal gland tissues (Van2021ZBTB32).


## References


[1. (Shin2017Transient) Hyun Mu Shin, Varun N. Kapoor, Gwanghun Kim, Peng Li, Hang-Rae Kim, M. Suresh, Susan M. Kaech, E. John Wherry, Liisa K. Selin, Warren J. Leonard, Raymond M. Welsh, and Leslie J. Berg. Transient expression of zbtb32 in anti-viral cd8+ t cells limits the magnitude of the effector response and the generation of memory. PLOS Pathogens, 13(8):e1006544, August 2017. URL: http://dx.doi.org/10.1371/journal.ppat.1006544, doi:10.1371/journal.ppat.1006544. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.ppat.1006544)

[2. (Zhu2018Regulation) Can Zhu, Ge Chen, Ying Zhao, Xiao-Ming Gao, and Jun Wang. Regulation of the development and function of b cells by zbtb transcription factors. Frontiers in Immunology, March 2018. URL: http://dx.doi.org/10.3389/fimmu.2018.00580, doi:10.3389/fimmu.2018.00580. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2018.00580)

[3. (Wang2021Fanconi) Shizhi Wang, Bo Ding, Mengjing Cui, Wenjing Yan, Qianqian Xia, Dan Meng, Siyuan Shen, Shuqian Xie, Hua Jin, and Xing Zhang. Fanconi anemia pathway genes advance cervical cancer via immune regulation and cell adhesion. Frontiers in Cell and Developmental Biology, November 2021. URL: http://dx.doi.org/10.3389/fcell.2021.734794, doi:10.3389/fcell.2021.734794. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.734794)

[4. (Jash2016ZBTB32) Arijita Jash, Yinan Wang, Florian J. Weisel, Christopher D. Scharer, Jeremy M. Boss, Mark J. Shlomchik, and Deepta Bhattacharya. Zbtb32 restricts the duration of memory b cell recall responses. The Journal of Immunology, 197(4):1159–1168, August 2016. URL: http://dx.doi.org/10.4049/jimmunol.1600882, doi:10.4049/jimmunol.1600882. This article has 44 citations.](https://doi.org/10.4049/jimmunol.1600882)

[5. (Van2021ZBTB32) Lise Van Wyngene, Tineke Vanderhaeghen, Ioanna Petta, Steven Timmermans, Katrien Corbeels, Bart Van der Schueren, Jolien Vandewalle, Kelly Van Looveren, Charlotte Wallaeys, Melanie Eggermont, Sylviane Dewaele, Leen Catrysse, Geert van Loo, Rudi Beyaert, Roman Vangoitsenhoven, Toshinori Nakayama, Jan Tavernier, Karolien De Bosscher, and Claude Libert. Zbtb32 performs crosstalk with the glucocorticoid receptor and is crucial in glucocorticoid responses to starvation. iScience, 24(7):102790, July 2021. URL: http://dx.doi.org/10.1016/j.isci.2021.102790, doi:10.1016/j.isci.2021.102790. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.isci.2021.102790)

[6. (Cheng2021ZBTB) Zhong-Yan Cheng, Ting-Ting He, Xiao-Ming Gao, Ying Zhao, and Jun Wang. Zbtb transcription factors: key regulators of the development, differentiation and effector function of t cells. Frontiers in Immunology, July 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.713294, doi:10.3389/fimmu.2021.713294. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.713294)

[7. (Jash2019ZBTB32) Arijita Jash, You W. Zhou, Diana K. Gerardo, Tyler J. Ripperger, Bijal A. Parikh, Sytse Piersma, Deepa R. Jamwal, Pawel R. Kiela, Adrianus C. M. Boon, Wayne M. Yokoyama, Chyi S. Hsieh, and Deepta Bhattacharya. Zbtb32 restrains antibody responses to murine cytomegalovirus infections, but not other repetitive challenges. Scientific Reports, October 2019. URL: http://dx.doi.org/10.1038/s41598-019-51860-z, doi:10.1038/s41598-019-51860-z. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-51860-z)

[8. (Upchurch2016Aberrant) Garland Michael Upchurch, Staci L. Haney, and Rene Opavsky. Aberrant promoter hypomethylation in cll: does it matter for disease development? Frontiers in Oncology, August 2016. URL: http://dx.doi.org/10.3389/fonc.2016.00182, doi:10.3389/fonc.2016.00182. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2016.00182)

[9. (Yoon2012ZBTB32) Hye Suk Yoon, Christopher D. Scharer, Parimal Majumder, Carl W. Davis, Royce Butler, Wendy Zinzow-Kramer, Ioanna Skountzou, Dimitrios G. Koutsonanos, Rafi Ahmed, and Jeremy M. Boss. Zbtb32 is an early repressor of the ciita and mhc class ii gene expression during b cell differentiation to plasma cells. The Journal of Immunology, 189(5):2393–2403, September 2012. URL: http://dx.doi.org/10.4049/jimmunol.1103371, doi:10.4049/jimmunol.1103371. This article has 76 citations.](https://doi.org/10.4049/jimmunol.1103371)